ConcertAI Launches Precision Suite™: Revolutionizing Oncology Insights with AI-Powered Solutions
ConcertAI, a leader in oncology-focused generative and agentic AI solutions, has unveiled its groundbreaking Precision Suite™, a family of AI-powered tools designed to transform how life sciences and healthcare organizations achieve actionable insights, optimize clinical trials, accelerate market execution, and improve patient outcomes. Leveraging the power of ConcertAI’s proprietary CARAai™ platform and its unparalleled depth of integrated oncology data, the Precision Suite™ delivers rapid, persona-tailored insights and enterprise-wide value, saving millions in costs while driving innovation.
Redefining Oncology Research and Commercialization
The Precision Suite™ is built on CARAai’s multi-modal, AI-curated data architecture, which translates complex medical and genomic data into precise, real-world applications. This innovative platform integrates assistants, agents, large language models (LLMs), and logical reasoning models (LRMs) specifically trained for life sciences and healthcare use cases. By seamlessly combining diverse data types—such as electronic medical records (EMRs), claims data, social determinants of health (SDOH), and genomic information—the suite enables faster decision-making, evidence-backed strategies, and maximum strategic impact.
At launch, the Precision Suite™ includes three powerful applications tailored to distinct use cases across the healthcare ecosystem: Precision Explorer™, Precision Trials™, and Precision GTM™. Together, these tools empower teams to unlock insights, streamline operations, and drive better patient outcomes.
Precision Explorer™: Accelerating Research and Insights
Precision Explorer™ is designed to empower Health Economics and Outcomes Research (HEOR), epidemiology, and medical teams by enabling them to uncover actionable insights within minutes. Using generative AI and intuitive interfaces, this tool streamlines cohort creation, outcomes analysis, and hypothesis testing, delivering insights twice as fast as traditional methods.
By leveraging curated oncology data aligned with industry standards like ASCO® guidelines, Precision Explorer™ ensures high-quality, citation-backed results. This not only accelerates research but also saves customers millions in operational costs, making it an indispensable tool for life sciences organizations.
Precision Trials™: Transforming Clinical Trial Operations
Clinical trials are often plagued by delays, costly amendments, and recruitment challenges. Precision Trials™ addresses these pain points by enabling smarter, faster decisions in study design, site selection, and patient recruitment. Powered by dynamic AI agents, this solution provides real-time assessments, reducing trial timelines and ensuring diversity and enrollment goals are met.
With CARAai’s advanced data-processing capabilities, Precision Trials™ can deliver $4M+ in cost savings for Phase II and III studies. By minimizing costly amendments and improving site performance, this tool accelerates the path to regulatory approval and market entry for life-saving therapies.
Precision GTM™: Driving Commercialization Success
For oncology therapies, commercialization is as critical as development. Precision GTM™ unifies fragmented clinical, claims, and SDOH data to provide a comprehensive view of treatment landscapes. Harnessing CARAai’s multi-modal insights, this platform enables brand teams to track real-time standards of care, physician trends, and treatment pathways.
By accelerating decision-making and enabling timely engagement, Precision GTM™ helps teams execute go-to-market strategies faster and more effectively. For a typical oncology brand, this translates to up to $7M in value generation, ensuring therapies reach patients sooner and with greater impact.
Precision360™: The Backbone of the Suite
Underpinning the Precision Suite™ is Precision360™, a revolutionary dataset that integrates EMR, genomic, claims, and SDOH data. With AI-driven curation and a recency of less than a week, Precision360™ provides real-time access to actionable insights, eliminating delays in oncology research and decision-making.
Designed for speed, accuracy, and reliability—even in complex, unstructured datasets—Precision360™ ensures that life sciences teams have the most up-to-date and relevant information at their fingertips. This backbone supports all applications within the Precision Suite™, enabling seamless workflows and consistent results.
Leadership Perspectives: A Commitment to Innovation
“Precision Suite™ is a testament to our commitment to innovation and patient-first outcomes,” said Eron Kelly, CEO of ConcertAI. “Its ability to process complex, diverse datasets in near real-time allows us to deliver immediately actionable insights that save customers millions in costs while accelerating their time to market for life-saving therapeutics. These new SaaS products are all built on our CARAai platform, the leading agentic AI platform designed specifically for the needs of the life sciences enterprise.”
Jeff Elton, Ph.D., Vice Chairman of ConcertAI, added: “ConcertAI serves 75% of the top life science companies and more than 50% of the largest global healthcare providers. This launch signifies the evolution of ConcertAI from providing specialized solutions to delivering enterprise-class SaaS tools. Precision Suite™ aligns our expertise with our mission to deliver scalable, impactful solutions that redefine what’s possible in life sciences and healthcare today.”
Availability and Impact
- Precision Explorer™ and Precision Trials™ will be available starting June 30, 2025.
- Precision GTM™ will follow with availability by July 31, 2025.
With these cutting-edge solutions, ConcertAI solidifies its position as the leader in generative and agentic AI tailored for oncology and broader life sciences applications. By combining the power of AI with the depth of oncology data, the Precision Suite™ is poised to revolutionize the way life sciences and healthcare organizations operate, ultimately improving patient outcomes and advancing the future of oncology.
Why Choose Precision Suite™?
For organizations seeking to accelerate insights, optimize operations, and drive better patient outcomes, the Precision Suite™ offers unmatched value. Its AI-powered tools, powered by CARAai™ and backed by ConcertAI’s extensive oncology data, provide rapid, accurate, and actionable insights across the healthcare ecosystem. Whether you’re conducting research, running clinical trials, or commercializing therapies, the Precision Suite™ empowers you to achieve your goals faster, smarter, and at scale.
